# Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer

**Category:** Health
**Source:** [https://jamanetwork.com/journals/jama](https://jamanetwork.com/journals/jama)
**Publisher:** JAMA
**Published:** Feb 19, 2026
**Scraped (UTC):** 2026-02-25T13:05:49+00:00

## Summary
New research published on overall survival comparing first-line versus second-line use of CDK4/6 inhibitors in advanced breast cancer patients.

## Full Article
*(Article text could not be extracted. Visit source link above.)*

---

*Content scraped from public sources with attribution. Users assume all risk.*  
*Auto-generated by [Perplexity News Tracker](https://github.com/myidkd1-coder/perplexity-news-tracker)*